Recombinant VWF Proteins for Prolonged Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for von Willebrand disease (VWD) and hemophilia A are limited by the short half-life of von Willebrand factor (VWF) and coagulation factor VIII (FVIII), leading to frequent dosing and potential bleeding complications.
Innovation Solution
Development of recombinant VWF proteins with specific mutations that enhance binding affinity to FVIII and prolong half-life, combined with artificial FVIII sequences, to create a therapeutic complex that mimics the natural VWF-FVIII interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous protein replacement is used to treat hemophilia A and von Willebrand disease, then bleeding symptoms can be managed, but frequent dosing is required due to short half-life of VWF and FVIII
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of VWF through specific mutations (e.g., N2463Q, N2463E substitutions) to alter its pharmacokinetic properties. These mutations reduce binding affinity to clearance receptors like ASGPR and LRP1, thereby extending the half-life of VWF and FVIII in circulation without compromising their hemostatic function.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining mutated VWF with FVIII to form a stable complex. This composite structure leverages the extended half-life of the mutated VWF to protect and prolong the circulation time of FVIII, achieving sustained bleeding control with reduced dosing frequency.
2Duration of action of moving object
If post-translational modifications like PEGylation or Fc fusion are applied to FVIII, then half-life is marginally enhanced, but these modifications reduce clearance rate of unbound FVIII with negligible effect on FVIII in complex with VWF
Solution Approach 1:
The patent extracts the half-life extension function from FVIII itself and transfers it to VWF through mutations. Instead of modifying FVIII with complex post-translational modifications, the invention modifies VWF to have intrinsic long circulation properties, which then naturally prolong FVIII half-life through complex formation.
3Duration of action of moving object
If VWF clearance is reduced by mutations in glycosylation sites, then half-life is extended, but these mutations may interfere with FVIII binding or platelet activation
Solution Approach 1:
The patent applies local quality by making site-specific mutations only in regions of VWF that are involved in clearance (such as glycosylation sites in the D'D3 and A1 domains) while preserving the integrity of functional domains responsible for FVIII binding and platelet activation. This localized modification approach extends half-life without compromising essential functions.
4Reliability
If frequent dosing is administered to maintain therapeutic levels, then bleeding control is maintained, but patient compliance decreases and bleeding complications may still occur
Solution Approach 1:
By changing the pharmacokinetic parameters of VWF through mutations that extend half-life, the patent enables less frequent dosing intervals while maintaining therapeutic blood levels, thereby improving patient compliance and reducing the risk of bleeding complications between doses.
Data Source
AI summary
A recombinant von Willebrand Factor (VWF) protein comprising one or more mutations and uses thereof are described. A recombinant protein complex comprising a von Willebrand factor sequence and one artificial Factor VIII sequence is described. A recombinant protein complex comprising a Factor VIII sequence and one artificial von Willebrand sequence is described. A recombinant protein complex is described that includes one artificial von Willebrand factor sequence and one artificial Factor VIII sequence. Also described are nucleic acid sequences and a vector encoding a VWF sequence and a pharmaceutical composition for inducing blood clotting that includes a VWF protein.